A	O
phase	B:C0282460
2	I:C0282460
trial	I:C0282460
of	O
pomalidomide	O
and	O
dexamethasone	O
rescue	O
treatment	O
in	O
patients	O
with	O
AL	O
amyloidosis	I:C0268381
.	O

A	O
phase	O
2	I:C0282460
trial	I:C0282460
of	O
pomalidomide	B:C2347624
and	O
dexamethasone	O
rescue	O
treatment	O
in	O
patients	O
with	O
AL	O
amyloidosis	I:C0268381
.	O

A	O
phase	O
2	I:C0282460
trial	I:C0282460
of	O
pomalidomide	O
and	O
dexamethasone	B:C0011777
rescue	O
treatment	O
in	O
patients	O
with	O
AL	O
amyloidosis	I:C0268381
.	O

A	O
phase	O
2	I:C0282460
trial	I:C0282460
of	O
pomalidomide	O
and	O
dexamethasone	O
rescue	O
treatment	O
in	O
patients	O
with	O
AL	B:C0268381
amyloidosis	I:C0268381
.	O

Immunomodulatory	B:C1527392
drugs	O
are	O
active	O
agents	O
in	O
light	O
-	I:C0342606
chain	I:C0342606
(	I:C0342606
AL	I:C0342606
)	I:C0342606
amyloidosis	I:C0342606
.	O

Immunomodulatory	O
drugs	B:C1254351
are	O
active	O
agents	O
in	O
light	O
-	I:C0342606
chain	I:C0342606
(	I:C0342606
AL	I:C0342606
)	I:C0342606
amyloidosis	I:C0342606
.	O

Immunomodulatory	O
drugs	O
are	O
active	O
agents	B:C0450442
in	O
light	O
-	I:C0342606
chain	I:C0342606
(	I:C0342606
AL	I:C0342606
)	I:C0342606
amyloidosis	I:C0342606
.	O

Immunomodulatory	O
drugs	O
are	O
active	O
agents	O
in	O
light	B:C0342606
-	I:C0342606
chain	I:C0342606
(	I:C0342606
AL	I:C0342606
)	I:C0342606
amyloidosis	I:C0342606
.	O

However	O
,	O
previous	O
studies	B:C2603343
could	O
not	O
show	O
a	O
survival	O
advantage	O
for	O
patients	O
with	O
AL	O
amyloidosis	I:C0268381
responding	O
to	O
salvage	O
treatment	I:C0085405
with	O
pomalidomide	O
.	O

However	O
,	O
previous	O
studies	O
could	O
not	O
show	O
a	O
survival	O
advantage	O
for	O
patients	O
with	O
AL	B:C0268381
amyloidosis	I:C0268381
responding	O
to	O
salvage	O
treatment	I:C0085405
with	O
pomalidomide	O
.	O

However	O
,	O
previous	O
studies	O
could	O
not	O
show	O
a	O
survival	O
advantage	O
for	O
patients	O
with	O
AL	O
amyloidosis	I:C0268381
responding	B:C1704632
to	O
salvage	O
treatment	I:C0085405
with	O
pomalidomide	O
.	O

However	O
,	O
previous	O
studies	O
could	O
not	O
show	O
a	O
survival	O
advantage	O
for	O
patients	O
with	O
AL	O
amyloidosis	I:C0268381
responding	O
to	O
salvage	B:C0085405
treatment	I:C0085405
with	O
pomalidomide	O
.	O

However	O
,	O
previous	O
studies	O
could	O
not	O
show	O
a	O
survival	O
advantage	O
for	O
patients	O
with	O
AL	O
amyloidosis	I:C0268381
responding	O
to	O
salvage	O
treatment	I:C0085405
with	O
pomalidomide	B:C2347624
.	O

In	O
this	O
phase	B:C0282460
2	I:C0282460
trial	I:C0282460
,	O
we	O
assessed	O
the	O
safety	O
and	O
efficacy	O
of	O
pomalidomide	O
and	O
dexamethasone	O
(	O
pomalidomide	O
and	I:C0011777
dexamethasone	I:C0011777
)	O
in	O
patients	O
with	O
AL	O
amyloidosis	I:C0268381
who	O
were	O
previously	O
exposed	O
to	O
bortezomib	O
,	O
alkylators	O
,	O
and	O
other	O
immunomodulatory	O
drugs	O
.	O

In	O
this	O
phase	O
2	I:C0282460
trial	I:C0282460
,	O
we	O
assessed	O
the	O
safety	O
and	O
efficacy	O
of	O
pomalidomide	B:C2347624
and	O
dexamethasone	O
(	O
pomalidomide	O
and	I:C0011777
dexamethasone	I:C0011777
)	O
in	O
patients	O
with	O
AL	O
amyloidosis	I:C0268381
who	O
were	O
previously	O
exposed	O
to	O
bortezomib	O
,	O
alkylators	O
,	O
and	O
other	O
immunomodulatory	O
drugs	O
.	O

In	O
this	O
phase	O
2	I:C0282460
trial	I:C0282460
,	O
we	O
assessed	O
the	O
safety	O
and	O
efficacy	O
of	O
pomalidomide	O
and	O
dexamethasone	B:C0011777
(	O
pomalidomide	O
and	I:C0011777
dexamethasone	I:C0011777
)	O
in	O
patients	O
with	O
AL	O
amyloidosis	I:C0268381
who	O
were	O
previously	O
exposed	O
to	O
bortezomib	O
,	O
alkylators	O
,	O
and	O
other	O
immunomodulatory	O
drugs	O
.	O

In	O
this	O
phase	O
2	I:C0282460
trial	I:C0282460
,	O
we	O
assessed	O
the	O
safety	O
and	O
efficacy	O
of	O
pomalidomide	O
and	O
dexamethasone	O
(	O
pomalidomide	B:C0011777
and	I:C0011777
dexamethasone	I:C0011777
)	O
in	O
patients	O
with	O
AL	O
amyloidosis	I:C0268381
who	O
were	O
previously	O
exposed	O
to	O
bortezomib	O
,	O
alkylators	O
,	O
and	O
other	O
immunomodulatory	O
drugs	O
.	O

In	O
this	O
phase	O
2	I:C0282460
trial	I:C0282460
,	O
we	O
assessed	O
the	O
safety	O
and	O
efficacy	O
of	O
pomalidomide	O
and	O
dexamethasone	O
(	O
pomalidomide	O
and	I:C0011777
dexamethasone	I:C0011777
)	O
in	O
patients	O
with	O
AL	B:C0268381
amyloidosis	I:C0268381
who	O
were	O
previously	O
exposed	O
to	O
bortezomib	O
,	O
alkylators	O
,	O
and	O
other	O
immunomodulatory	O
drugs	O
.	O

In	O
this	O
phase	O
2	I:C0282460
trial	I:C0282460
,	O
we	O
assessed	O
the	O
safety	O
and	O
efficacy	O
of	O
pomalidomide	O
and	O
dexamethasone	O
(	O
pomalidomide	O
and	I:C0011777
dexamethasone	I:C0011777
)	O
in	O
patients	O
with	O
AL	O
amyloidosis	I:C0268381
who	O
were	O
previously	O
exposed	O
to	O
bortezomib	B:C1176309
,	O
alkylators	O
,	O
and	O
other	O
immunomodulatory	O
drugs	O
.	O

In	O
this	O
phase	O
2	I:C0282460
trial	I:C0282460
,	O
we	O
assessed	O
the	O
safety	O
and	O
efficacy	O
of	O
pomalidomide	O
and	O
dexamethasone	O
(	O
pomalidomide	O
and	I:C0011777
dexamethasone	I:C0011777
)	O
in	O
patients	O
with	O
AL	O
amyloidosis	I:C0268381
who	O
were	O
previously	O
exposed	O
to	O
bortezomib	O
,	O
alkylators	B:C0002073
,	O
and	O
other	O
immunomodulatory	O
drugs	O
.	O

In	O
this	O
phase	O
2	I:C0282460
trial	I:C0282460
,	O
we	O
assessed	O
the	O
safety	O
and	O
efficacy	O
of	O
pomalidomide	O
and	O
dexamethasone	O
(	O
pomalidomide	O
and	I:C0011777
dexamethasone	I:C0011777
)	O
in	O
patients	O
with	O
AL	O
amyloidosis	I:C0268381
who	O
were	O
previously	O
exposed	O
to	O
bortezomib	O
,	O
alkylators	O
,	O
and	O
other	O
immunomodulatory	B:C1527392
drugs	O
.	O

In	O
this	O
phase	O
2	I:C0282460
trial	I:C0282460
,	O
we	O
assessed	O
the	O
safety	O
and	O
efficacy	O
of	O
pomalidomide	O
and	O
dexamethasone	O
(	O
pomalidomide	O
and	I:C0011777
dexamethasone	I:C0011777
)	O
in	O
patients	O
with	O
AL	O
amyloidosis	I:C0268381
who	O
were	O
previously	O
exposed	O
to	O
bortezomib	O
,	O
alkylators	O
,	O
and	O
other	O
immunomodulatory	O
drugs	B:C1254351
.	O

Three	O
patients	O
received	O
pomalidomide	B:C2347624
2	O
mg/d	O
with	O
no	O
dose	O
-	O
limiting	O
toxicity	O
.	O

Pomalidomide	B:C2347624
was	O
administered	O
continuously	O
and	O
dexamethasone	O
was	O
given	O
once	O
per	O
week	O
at	O
a	O
dose	O
of	O
20	O
or	O
40	O
mg	O
.	O

Pomalidomide	O
was	O
administered	O
continuously	O
and	O
dexamethasone	B:C0011777
was	O
given	O
once	O
per	O
week	O
at	O
a	O
dose	O
of	O
20	O
or	O
40	O
mg	O
.	O

Fifteen	O
patients	O
experienced	O
grade	O
3	O
to	O
4	O
adverse	B:C0877248
events	I:C0877248
;	O
the	O
most	O
common	O
were	O
fluid	O
retention	I:C0268000
and	O
infection	O
.	O

Fifteen	O
patients	O
experienced	O
grade	O
3	O
to	O
4	O
adverse	O
events	I:C0877248
;	O
the	O
most	O
common	O
were	O
fluid	B:C0268000
retention	I:C0268000
and	O
infection	O
.	O

Fifteen	O
patients	O
experienced	O
grade	O
3	O
to	O
4	O
adverse	O
events	I:C0877248
;	O
the	O
most	O
common	O
were	O
fluid	O
retention	I:C0268000
and	O
infection	B:C3714514
.	O

Hematologic	B:C4054793
response	I:C4054793
was	O
observed	O
in	O
68	O
%	O
of	O
patients	O
(	O
very	O
good	O
partial	O
response	I:C1521726
or	O
complete	O
response	I:C1275810
in	O
29	O
%	O
)	O
,	O
as	O
well	O
as	O
improved	O
survival	O
.	O

Hematologic	O
response	I:C4054793
was	O
observed	O
in	O
68	O
%	O
of	O
patients	O
(	O
very	O
good	O
partial	B:C1521726
response	I:C1521726
or	O
complete	O
response	I:C1275810
in	O
29	O
%	O
)	O
,	O
as	O
well	O
as	O
improved	O
survival	O
.	O

Hematologic	O
response	I:C4054793
was	O
observed	O
in	O
68	O
%	O
of	O
patients	O
(	O
very	O
good	O
partial	O
response	I:C1521726
or	O
complete	B:C1275810
response	I:C1275810
in	O
29	O
%	O
)	O
,	O
as	O
well	O
as	O
improved	O
survival	O
.	O

Median	O
time	O
to	O
response	B:C1704632
was	O
1	O
month	O
.	O

pomalidomide	B:C0011777
and	I:C0011777
dexamethasone	I:C0011777
is	O
a	O
rapidly	O
active	O
regimen	O
and	O
improves	O
survival	O
in	O
responding	O
,	O
heavily	O
pretreated	O
patients	O
with	O
AL	O
amyloidosis	I:C0268381
.	O

pomalidomide	O
and	I:C0011777
dexamethasone	I:C0011777
is	O
a	O
rapidly	O
active	O
regimen	B:C0040808
and	O
improves	O
survival	O
in	O
responding	O
,	O
heavily	O
pretreated	O
patients	O
with	O
AL	O
amyloidosis	I:C0268381
.	O

pomalidomide	O
and	I:C0011777
dexamethasone	I:C0011777
is	O
a	O
rapidly	O
active	O
regimen	O
and	O
improves	O
survival	O
in	O
responding	B:C1704632
,	O
heavily	O
pretreated	O
patients	O
with	O
AL	O
amyloidosis	I:C0268381
.	O

pomalidomide	O
and	I:C0011777
dexamethasone	I:C0011777
is	O
a	O
rapidly	O
active	O
regimen	O
and	O
improves	O
survival	O
in	O
responding	O
,	O
heavily	O
pretreated	O
patients	O
with	O
AL	B:C0268381
amyloidosis	I:C0268381
.	O

This	O
trial	B:C0008976
was	O
registered	O
at	O
www.clinicaltrials.gov	O
as	O
#	O
NCT01510613	I:C0282574
.	O

This	O
trial	O
was	O
registered	B:C1514821
at	O
www.clinicaltrials.gov	O
as	O
#	O
NCT01510613	I:C0282574
.	O

This	O
trial	O
was	O
registered	O
at	O
www.clinicaltrials.gov	B:C0282574
as	O
#	O
NCT01510613	I:C0282574
.	O

This	O
trial	O
was	O
registered	O
at	O
www.clinicaltrials.gov	O
as	O
#	B:C0282574
NCT01510613	I:C0282574
.	O

